Image source: The Motley Fool. Wednesday, Feb. 4, 2026 at 8:30 a.m. ET Call participants Chief Executive Officer — Robert Mauch Chief Financial Officer — James Cleary Takeaways Adjusted Diluted EPS -- $4.08, representing a 9% increase, attributed mainly to U.S. Healthcare Solutions segment performance. -- $4.08, representing a 9% increase, attributed mainly to U.S. Healthcare Solutions segment per...
Image source: The Motley Fool. Wednesday, Feb. 4, 2026 at 8:30 a.m. ET Call participants Chief Executive Officer — Robert Mauch Chief Financial Officer — James Cleary Takeaways Adjusted Diluted EPS -- $4.08, representing a 9% increase, attributed mainly to U.S. Healthcare Solutions segment performance. -- $4.08, representing a 9% increase, attributed mainly to U.S. Healthcare Solutions segment performance. Consolidated Revenue -- $85.9 billion, up 5.5%, reflecting growth in both reportable segments and other business lines. -- $85.9 billion, up 5.5%, reflecting growth in both reportable segments and other business lines. U.S. Healthcare Solutions Revenue -- $76.2 billion, a 5% rise, driven by higher volumes in GLP-1 products, specialty sales, and health system partnerships. -- $76.2 billion, a 5% rise, driven by higher volumes in GLP-1 products, specialty sales, and health system partnerships. GLP-1 Product Sales -- Grew by $1 billion, an 11% increase, evidencing heightened specialty utilization in the U.S. market. -- Grew by $1 billion, an 11% increase, evidencing heightened specialty utilization in the U.S. market. Consolidated Gross Profit -- $3 billion, up 18%, primarily due to the U.S. Healthcare Solutions segment. -- $3 billion, up 18%, primarily due to the U.S. Healthcare Solutions segment. Gross Profit Margin -- 3.48%, an improvement of 37 basis points, mainly influenced by the Retina Consultants of America (RCA) acquisition. -- 3.48%, an improvement of 37 basis points, mainly influenced by the Retina Consultants of America (RCA) acquisition. Operating Expenses -- $1.9 billion, an approximately 22% increase, primarily from the RCA acquisition and overall revenue support. -- $1.9 billion, an approximately 22% increase, primarily from the RCA acquisition and overall revenue support. Consolidated Operating Income -- $1.1 billion, 12% higher, driven by both RCA acquisition impact and U.S. Healthcare Solutions growth. -- $1.1 billion, 12% higher, driven by both R...